Sign In
Buy RMD
$214.29
+5.33 (+2.55%)
At Close: Jul 29, 2026
American Capital Management Inc. Has $59.58 Million Position in ResMed Inc. $RMD
04:19am, Tuesday, 28'th Jul 2026
American Capital Management Inc. cut its stake in ResMed Inc. (NYSE: RMD) by 13.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
04:40pm, Tuesday, 21'st Jul 2026
TROY, Mich., July 21, 2026 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Broadridge Financial Resources Inc. (NYSE: BR) as its "Sto
Baader Bank Aktiengesellschaft Trims Position in ResMed Inc. $RMD
04:01am, Tuesday, 21'st Jul 2026
Baader Bank Aktiengesellschaft decreased its stake in shares of ResMed Inc. (NYSE: RMD) by 61.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commissi
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Monday, 13'th Jul 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
01:56pm, Friday, 10'th Jul 2026
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
ResMed Analyst Backs Portfolio Reset
02:03pm, Thursday, 09'th Jul 2026
ResMed Inc. (NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 08'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top 50 High-Quality Dividend Growth Stocks For July 2026
07:42am, Wednesday, 08'th Jul 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable univer
ResMed to sell software business MatrixCare for $490 million
06:07pm, Tuesday, 07'th Jul 2026
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its f
Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare
05:06pm, Tuesday, 07'th Jul 2026
SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to a
Resmed Announces Agreement to Sell MatrixCare Business
04:30pm, Tuesday, 07'th Jul 2026
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ente
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Tuesday, 07'th Jul 2026
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
11:40am, Tuesday, 07'th Jul 2026
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down
Here's Why ResMed (RMD) is a Strong Growth Stock
10:45am, Tuesday, 07'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ResMed (RMD) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 01'st Jul 2026
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
